

BAXTER INTERNATIONAL INC.
Key Product Line Sales at Actual and Constant Foreign Exchange Rates
Periods Ending December 31, 2007 and 2006
(unaudited)
(\$ in millions)

	Q4 2007	Q4 2006 ¹	% Growth @ Actual Rates	% Growth @ Constant Rates	YTD 2007	YTD 2006 ¹	% Growth @ Actual Rates	% Growth @ Constant Rates
BioScience								
Recombinants ²	\$463	\$405	14%	9%	\$1,714	\$1,523	13%	8%
Plasma Proteins ³	301	262	15%	8%	1,015	881	15%	10%
Antibody Therapy	280	207	35%	30%	985	785	25%	23%
Regenerative Medicine ⁴	95	78	22%	17%	346	298	16%	12%
Other ⁵	70	90	(22%)	(30%)	510	393	30%	21%
Total BioScience⁶	\$1,209	\$1,042	16%	10%	\$4,570	\$3,880	18%	13%
Medication Delivery								
IV Therapies ⁷	\$390	\$341	14%	6%	\$1,402	\$1,285	9%	3%
Global Injectables ⁸	390	374	4%	0%	1,504	1,453	4%	0%
Infusion Systems	236	221	7%	2%	860	817	5%	2%
Anesthesia ⁹	126	92	37%	32%	422	317	33%	29%
Other ¹⁰	13	11	18%	18%	43	45	(4%)	(7%)
Total Medication Delivery	\$1,155	\$1,039	11%	5%	\$4,231	\$3,917	8%	4%
Renal								
PD Therapy	\$481	\$429	12%	5%	\$1,791	\$1,634	10%	5%
HD Therapy	120	108	11%	2%	448	431	4%	(2%)
Total Renal	\$601	\$537	12%	4%	\$2,239	\$2,065	8%	4%
Baxter excluding Transfusion Therapies	\$2,965	\$2,618	13%	7%	\$11,040	\$9,862	12%	8%
Transfusion Therapies¹¹	\$44	\$145	(70%)	(70%)	\$223	\$516	(57%)	(58%)
TOTAL BAXTER	\$3,009	\$2,763	9%	3%	\$11,263	\$10,378	9%	4%

¹ Prior year sales data has been reclassified to reflect the changes that are described in Notes 2, 5, 6, 8, 9 and 11 below.

² Includes sales of recombinant FVIII products (ADVATE and RECOMBINATE). Sales of recombinant FIX (BeneFIX) were previously reported in Recombinants and are now reported in Other, as detailed below.

³ Includes plasma-derived hemophilia (FVII, FVIII, FIX and FEIBA), albumin, and certain other plasma-based products.

⁴ Previously referred to as BioSurgery.

⁵ Principally includes vaccines, sales of plasma to third parties, and recombinant FIX (BeneFIX). Sales of recombinant FIX were previously reported in Recombinants.

⁶ BioScience sales have been reclassified to reflect the change described in Note 11.

⁷ Principally includes intravenous solutions and nutritional products.

⁸ Principally includes sales related to the pharmaceutical partnering business, enhanced packaging, premix drugs and generic injectables. Generic injectables were previously reported in Anesthesia.

⁹ Principally includes proprietary inhaled anesthetics and other anesthesia products. Sales of generic injectables were previously reported in Anesthesia and are now reported in Global Injectables.

¹⁰ Principally includes other hospital-distributed products.

¹¹ The Transfusion Therapies (TT) business was sold on February 28, 2007. The results of operations of the TT business were previously reported in the BioScience business. Due to Baxter's actual and expected significant continuing cash flows associated with this business, Baxter continued to include the results of operations of the TT business in the company's results of continuing operations through the divestiture date. The TT totals above include sales of TT products through the date of divestiture, as well as post-divestiture revenues associated with manufacturing, distribution and other services provided by the company to the buyer of the TT business post-divestiture.